chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This is a spontaneous report from a contactable consumer (patient). A female patient, of an unspecified age, received the 1st dose of BNT162B2 (Pfizer-BioNTech COVID-19 mRNA vaccine, solution for injection), via an unspecified route of administration, on an unspecified date, single dose, for COVID-19 immunisation. The patient's medical history and concomitant medications not reported. On an unspecified date (five days after the vaccination), patient experienced swollen lymph node in throat on the opposite side of the injection site. The patient wanted to know what to expect on the second dose of the vaccine. The outcome of the event: unknown. No follow-up attempts possible. Information about lot/batch number cannot be obtained. No further information expected.
The vaccine was administered at approx 9:10am, her symptoms started 2 hours later. Her left arm was hard, hot and sore. She had chills and a fever of 100. By evening it was really hot and red and she went to bed early. Arm was hard up to the arm pit on outside and red inside, Entire arm had a red streak. Hot until 10/18/06
pain; This is a spontaneous report from a non-contactable consumer from a sponsored program. A male patient of an unknown age received 2nd dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) at single dose via an unknown route on an unknown date for Covid-19 immunization. Medical history and concomitant drug were not provided. Patient took ibuprofen same day as his second dose schedule due to pain related issue. Outcome of the event was unknown.  No follow up attempts are possible. No further information is expected.
Patient   received the Pfizer vaccine on 11/6/2021 at 11:55am   at 12 noon., he slumped over in his chair.  He was shaky and sweaty.   Brought gurney over and transferred patient.     vital signs: 12:07   133/88.73                    12:13 99/64 , 81                     12:25 122/73  55                      12:35 107/40  53, Spo2 100%  This was patients first dose.  He never had an adverse reaction to any other vaccines.  NKDA.   Only Seasonal allergies No other illnesses at time of vaccination  No chronic health conditions at time of vaccination  Patient was accompanied by friend (who is a MA) Patient instructed to let nurse know that when he gets second vaccine what happened and that we would administer on cart. He had two bottles of water. V.S stable, color good, skin dry
Received vaccine past its 30-days Exp date Vaccines went into 2-8 C thaw state on or about 24-Dec-2021; Received vaccine past its 30-days Exp date Vaccines went into 2-8 C thaw state on or about 24-Dec-2021; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Received vaccine past its 30-days Exp date Vaccines went into 2-8 C thaw state on or about 24-Dec-2021) and PRODUCT STORAGE ERROR (Received vaccine past its 30-days Exp date Vaccines went into 2-8 C thaw state on or about 24-Dec-2021) in a 22-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 066H21A) for COVID-19 vaccination.     It was unknown if patient had any acute illnesses at the time of vaccination and up to one month before. It was unknown if the patient had chronic or long-standing health conditions.     On 19-Mar-2022 at 2:16 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 19-Mar-2022 at 2:16 PM, the patient experienced EXPIRED PRODUCT ADMINISTERED (Received vaccine past its 30-days Exp date Vaccines went into 2-8 C thaw state on or about 24-Dec-2021). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Received vaccine past its 30-days Exp date Vaccines went into 2-8 C thaw state on or about 24-Dec-2021). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Received vaccine past its 30-days Exp date Vaccines went into 2-8 C thaw state on or about 24-Dec-2021) and PRODUCT STORAGE ERROR (Received vaccine past its 30-days Exp date Vaccines went into 2-8 C thaw state on or about 24-Dec-2021) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter. It was unknown if any prescriptions, over-the-counter-medications, dietary supplements, or herbal remedies were being taken by the patient at the time of vaccination and/or at the time of the adverse event. It was unknown if other vaccines were given on the same day or within one month prior to any dose of as Moderna COVID-19 Vaccine to the patient. The patient received booster dose. The patient received Moderna vaccine past its 30 day of expiry date. Vaccine went into 2 to 8 degree Celsius thaw state on or about 24-Dec-2021. This vaccine was administered up until its manufacturing expiry date of 04-Apr-2022. We no longer possess this lot number. No treatment information was provided.   This case was linked to MOD-2022-542869 (Patient Link).
pt called agency Friday AM 22MAY92 to report swelling, pain area 10 cm rt deltoid inject site; advised MD APAP; seen in ER by MD placed on Duracef; 27MAY92 site viewed area 5cm pink, no induration w/lump over inject site;
Pt came into Emergency Department with resuscitation efforts in progress. Patient spouse states no known health concerns but was feeling unwell after 2nd dose of vaccine on Monday.
10 mins after pfizer vaccine administration pt complained of needle phobia and dizziness. He stated that he has not eaten today. Pt was moved to the grown by staff and vial signs were obtained: 98/62, 98% r/a 54, 14. Water was provided and pt was observed by  staff until symptoms resolved. Pt was educated on importance of eating before vaccines and discharged home without further incidents
HCP reported PROQUAD was administered after a temperature excursion to one patient. Product was administered on Sep 27, 2023. No further information provided. No additional AE reported. No PQC reported.; No additional AE; This spontaneous report was received from a nurse and refers to a 10 year old male patient. The patient's concurrent conditions, medical history, concomitant medications, drug reactions or allergies were not reported.   On 27-SEP-2023, the patient was vaccinated with a dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live(PROQUAD) (lot # W036929, expiration date: 19-MAY-2024,  therapy type stablished as rHA) (strength, route of administration, anatomical location not provided) as prophylaxis; which underwent a temperature excursion (product storage error). No additional adverse events were reported.
Whole upper arm is red, swollen like a baseball, and hot to the touch. 101 fever and body aches and chills for 36 hours. Fever broke and aches stopped. Arm is still red and swollen.
Information has been received from a registered nurse concerning a 5 year old female with no known drug allergies and no prior medical history who on 07/31/2002 was vaccinated with a dose of measles virus vaccine live (+) mumps virus vaccine live (+) rubella virus vaccine live (second generation)(Lot # 642695/0490M).  Concomitant vaccination included a dose of diphtheria toxoid/pertussis vaccine/tetanus.  Subsequently the patient developed a rash "described as hot, red, swollen area".  It is reported that the "site reaction is consistent with DTaP vaccine and is definitely not MMR related".  It is not known if medical attention was sought.  It was also reported that two ther patients developed rashes after vaccination with measles virus vaccine live (+) mumps virus vaccine live (+) rubella virus vaccine live (second generation)(WAES # 0208USA10136 and WAES # 0208USA01577).  Additional information has been requested.
Severe pain in all joints, but especially in my shoulders, neck and hips. For about 4 hours, my arms were immobile at my sides. I couldn?t lift them or move them away from my body. The joint pain persisted for about four days, but my right shoulder is still painful.
got vaccine last 01/12/2021, first Moderna dose, was fine but L arm hurt at injection site; then, on either 1/13 or 01/14 morning (cannot remember), she woke up with a feeling of pressure "right in the middle of my chest". It has been consistently present since then, no pain.
Patient reported getting a rash around the neck area the day after receiving the vaccine. She self treated with a cold compress and cool water. She contacted her prescriber when the rash began to spread to her face, ears and arms. The prescriber gave a script for Prednisone. Prescriber is also doing blood work to check liver function due to Dress Syndrome.
Case number PHEH2014US016220, is an initial spontaneous report received from a pharmacist on 11 Aug 2014. This report refers to a 76 year old patient of unknown gender. The patient received FLUVIRIN (batch number: unknown) 0.5 ml intramuscularly on 09 Aug 2014. The pharmacist reported that the patient received FLUVIRIN from either an unopened MDV or an opened MDV after it reached 74.3F for 4-6 hours on 08 Aug 2014. No adverse event was reported. No further information was provided.
SARS-COV 19 Infection. Symptomatic: Cough, Congestion, Runny Nose, Fever, Loss of Smell, Headache, Sore throat, Fatigue, Chills, Muscle Aches.
Fever, severe sore throat, aches in joints - hips & back, nausea. Taken to Pediatrician on 9/21/2010.
None of the patients reported symptoms. No Additional AE's/PQC's were reported.; Improperly stored PEDVAXHIB has been administered to patients; This spontaneous report was received from a staff from an outpatient care, referring to a patient of unknown age and gender. The patient's pertinent medical history, drug reactions/allergies, concurrent condition and concomitant medication were not provided.  From 24-MAY-2021 to 25-MAY-2021, a temperature excursion occurred as haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAXHIB) (lot # T026067 has been verified to be a valid lot number, expiration date was reported as 01-APR-2023) was stored under 54.3 Fahrenheit (F) for 1 hour and 20 minutes, 55.0 F for 7 hours and 10 minutes and 56.8 F for 2 hours and 35 minutes. The temperature excursion was recorded by digital data logger. There was no previous temperature excursion. On 24-JUN-2021, the patient was vaccinated with the improperly stored vaccine (strength and route were not reported) 1 (unit not provided) for prophylaxis. The patient did not report symptoms. No additional adverse events (AE) or product quality complaints (PQC) were reported.  This is one of several reports received from the same reporter.
This spontaneous report as received from a 66 year old female retired nurse practitioner refers to herself with depression and allergic to tetanus toxoid (caused circulatory shutdown), Codeine, Morphine, DEMEROL, MOTRIN, COMPAZINE, PHENERGAN, TOFRANIL. On 05-JUL-2013 the patient was vaccinated subcutaneously with ZOSTAVAX (lot number, expiry date, dose, site unspecified). Concomitant therapies included PROZAC 40 mg once daily and VALIUM 5 mg once daily. On 06-JUL-2013, the patient experienced swelling around the injection site, redness, headache and extreme sensitivity to touch. She also reported that on 10-JUL-2013, she developed a "sensitivity" on the skin of her elbow that is sensitive to "all" touch. The symptoms she developed at the injection site were "gradually going away" and was now just pink at the injection site. The patient did not seek medical attention. She was treated with ALEVE (dosage unspecified). No laboratory diagnostics studies were performed. The outcome of the events was reported as recovering/resolving. Additional information has been requested.
Patient had Zoster vaccine on 7-8-08.  Went to doctor on 8-15-08 after having pain and 3-4 blisters on face for approximately 1 week and was dx with Shingles.  Dr. tx with Azithromycin pack and Prednisone at that time.  On 10-4-08, patient had a reoccurrence of Shingles in the waistline area and was seen by the doctor on 1--6-08 and was tx with Famciclovir 500mg TID x 3 days with 1 refill.  Patient still has lesions but much improved and pain is also lessened.
This spontaneous report as received from a medical assistant refers to a 16 year old patient of unknown gender. On 05-APR-2016, the patient was vaccinated with improperly stored dose of GARDASIL 9 (dose, anatomical location and route of administration were not provided, lot # L026602 with expiration date 19-OCT-2017). The vaccine underwent temperature excursion of either +1 or -1 degree Celsius for 255.5 total cumulative hours, which was detected by a data logger. There was no previous temperature excursion. No adverse effects were reported. This is one of several reports received from the same reporter. Additional information has been requested.
This case was reported by a healthcare professional and described the occurrence of autism in a 2 year old male subject who was vaccinated with diphtheria and tetanus toxoids and acellular pertussis vaccine absorbed vaccine for prophylaxis. The subject's medical history included some developmental delay. Previous and/or concurrent vaccination included Haemophilus influenzae type B vaccine; hepatitis B vaccine, inactivated poliomyelitis vaccine, MMR, varicella virus vaccine, and 7-valent conjugate pneumococcal vaccine. On 1/16/03, 3/17/03, 6/2/03, and 3/2/04, the subject received four doses of diphtheria and tetanus toxoids and acellular pertussis vaccine absorbed vaccine. The following lot numbers were provided (lot DTaP57B9, DTaP583B2, and DTaP592A9); however no specific date of administration of each was provided. Approximately eight months later, on an unspecified date in November 2004, the subject was diagnosed with autism. This case was assessed as medically serious (OMIC). At the time of reporting the event was unresolved.
lump at the injection site; Injection site warm to the touch; itchy  at the injection site; Redness at the injection site; raised surface at the injection site; Sore arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Sore arm), VACCINATION SITE MASS (lump at the injection site), VACCINATION SITE WARMTH (Injection site warm to the touch), VACCINATION SITE PRURITUS (itchy  at the injection site) and VACCINATION SITE ERYTHEMA (Redness at the injection site) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 034C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was provided by the reporter.  Concomitant products included LISINOPRIL for an unknown indication.    On 24-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-May-2021, the patient experienced PAIN IN EXTREMITY (Sore arm). On 02-Jun-2021, the patient experienced VACCINATION SITE MASS (lump at the injection site), VACCINATION SITE WARMTH (Injection site warm to the touch), VACCINATION SITE PRURITUS (itchy  at the injection site), VACCINATION SITE ERYTHEMA (Redness at the injection site) and VACCINATION SITE SWELLING (raised surface at the injection site). On 28-May-2021, PAIN IN EXTREMITY (Sore arm) had resolved. At the time of the report, VACCINATION SITE MASS (lump at the injection site), VACCINATION SITE WARMTH (Injection site warm to the touch), VACCINATION SITE PRURITUS (itchy  at the injection site), VACCINATION SITE ERYTHEMA (Redness at the injection site) and VACCINATION SITE SWELLING (raised surface at the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment medications were not provided by reporter.
SICK; This spontaneous report received from a patient via a company representative concerned a patient of unspecified age and sex. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported. On an unspecified date, the subject experienced sick. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of sick was not reported. This report was non-serious.
patient received a monovalent Pfizer-BioNTech and/or Moderna COVID-19 vaccine after April 18, 2023
Received vaccine at 3p.  At 9p started feeling nauseated with stomach cramping.  At midnight started vomiting .  After few hours it slowed down and then started vomiting again most of the day on 1/14.  Unable to keep anything down.  As of 1/15 was feeling better
rashes on arm pit where injection site is and around to her legs; rashes on arm pit where injection site is and around to her legs; joint pain; soreness around injection site; Fatigue; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE RASH (rashes on arm pit where injection site is and around to her legs), RASH (rashes on arm pit where injection site is and around to her legs), ARTHRALGIA (joint pain), VACCINATION SITE PAIN (soreness around injection site) and FATIGUE (Fatigue) in a 51-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concomitant products included TAMOXIFEN, GABAPENTIN and DICLOFENAC for an unknown indication.    On 02-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Mar-2021, the patient experienced VACCINATION SITE RASH (rashes on arm pit where injection site is and around to her legs), RASH (rashes on arm pit where injection site is and around to her legs), ARTHRALGIA (joint pain), VACCINATION SITE PAIN (soreness around injection site) and FATIGUE (Fatigue). At the time of the report, VACCINATION SITE RASH (rashes on arm pit where injection site is and around to her legs), RASH (rashes on arm pit where injection site is and around to her legs), ARTHRALGIA (joint pain), VACCINATION SITE PAIN (soreness around injection site) and FATIGUE (Fatigue) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
chills started Sat Morning 2 days after injection.  3 days after injection difficult to breathe and steroid and bronchodilator inhalers are not providing relief.  Phlegm and mucus coughing up and whistle wheezing on exhale.  Unable to walk or talk.  102 temperature Sunday morning and 89 oxygen level found at the finger tip.   Severe sinus congestion and closed airways.  Pounding joint and body aches and unable to move.  Confusion.  Nausea.  No appetite. Dizzy.
This case was reported by a physician and described the occurrence of nodule injection site in a 2-month-old male subject who was vaccinated with Pediarix (GlaxoSmithKline), Prevnar (Wyeth) for prophylaxis.  Concurrent vaccination included ActHib (Aventis) and RotaTeq (Merck) both given on 27 September 2007.  On 27 September 2007 the subject received 1st dose of Pediarix at 0.5 ml in the left thigh.  On 27 September 2007 the subject received 1st dose of Prevnar at a different site in the left thigh.  Approximately 2 to 3 days (28 September 2007), after vaccination with Pediarix and Prevnar, the subject developed a nodule at the injection site (3cm x 3xcm wide and 1cm in elevation).  At the time of reporting the event was unresolved.  The physician considered the event was probably related to vaccination with Pediarix.
Feb. 10th, vaccine given in the morning.  Sore arm at injection site that night and the next day.  Feb 11th, one time episode of projectile vomiting bile?  Feb. 19th, non erythematous rash started on back of the neck only and not itchy.  Feb 20th, widespread significant erythematous rash at the front and back of the torso only w itchiness.  Feb. 21st, rash extended to the groin, vulva, arms, legs, and face.  Still itchy.
20 Patients received Spikevax past the 30 day expiration date; No adverse event; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (20 Patients received Spikevax past the 30 day expiration date) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 023C22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (20 Patients received Spikevax past the 30 day expiration date) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (20 Patients received Spikevax past the 30 day expiration date) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (20 Patients received Spikevax past the 30 day expiration date).    No concomitant medications were reported. No treatment information was provided. The case contains information of 12th patient out of 20 patients.   This case was linked to US-MODERNATX, INC.-MOD-2023-700683 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-700683:Master case
patient states she started having tingling, numbness of extremities progressively getting worse and now with throbing pain of extremities.  First went to her primary care provider for these symptoms starting 8/06 (about a week after shots) has since been to a local neurologist and also sent to hospital neurology dept.  Patient just recently started looking at when she recieved immunizations for travel and when her symptoms started. Recieved multiple injections in short time frame for travel.  04/09/2007  MR received from Neuro. consult.  Several OVs from 3/30/2006 to 8/2/2006.  Vax given 8/22/2006 per VAERS report. 3/2006 OV with c/o cold hands, tingling feet, tight feeling in abdomen, dizziness, disorientation, sore neck with DX of CTS, Paresthesias, cold ? Raynauds, hypothyroid. OV 8/2/06 with c/o paresthesias of the hands. DX(8/2/06):  Possible cubital tunnel syndrome.  Paresthesias of unclear etiology. No eveidence of radiculopathy or myelopathy. No OVs after 8/2/06.
My 18yr old who was also vaccinated fully with Pfizer got Covid at school. I got it from my son. I lost all my taste and smell which hasn't completely return yet. I didn't have a fever or flu symptoms. I felt I was suffocating and couldn't breath. I was completely exhausted and tired but could not sleep at all. My nose wasn't clogged but my chest was completely full. I went to the hospital to get the antibody treatment. My heart rate was all jacked up and high and is still, I was put on beta blockers and stronger asthma medications and 8 different antibiotics to fight the symptoms so I can breathe but nothing worked. It's totally changed my life and being an athletic I'm not able to do what I've been doing for the last 20-30 years due to the complications caused by COVID.
Left upper extremity arm region 1 3/4"x1 1/2" (5cm round) red area, itching. Red rash non raised area Bilateral inner forearm and back of  neck. Benadryl taking with relief. 11/27/01 rash faded, red area left upper arm faded. Occasional itching. Still taking Benadryl.